Apogee Therapeutics (APGE) News Today

Victory Capital Management Inc. lifted its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 56.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 156,266 shares of the company's stock after purchasing an a

First Turn Management LLC lowered its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 16.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 318,327 shares of the company's stock af

TD Asset Management Inc trimmed its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 35.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 95,006 shares of the company's stock after selling 53,

Apogee Therapeutics (NASDAQ:APGE) Shares Up 5.2%

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 8,190,000 shares, a growth of 5.3% from the July 31st total of 7,780,000 shares. Approximately 22.0% of the company's shares are short sold. Based on an average trading volume of 443,300 shares, the short-interest ratio is currently 18.5 days.

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) CFO Jane Henderson sold 6,000 shares of the company's stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $48.26, for a total transaction of $289,560.00. Following the completion of the sale, the chief financial officer now owns 200,871 shares of the company's stock, valued at $9,694,034.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Apogee Therapeutics (NASDAQ:APGE) Trading 6.2% Higher

Apogee Therapeutics (NASDAQ:APGE) Shares Down 2.2%

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.60) EPS for the quarter, meeting analysts' consensus estimates of ($0.60).

Apogee Therapeutics (NASDAQ:APGE) Trading Up 7%

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 7,335 shares of the company's stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $40.67, for a total value of $298,314.45. Following the sale, the insider now owns 287,458 shares of the company's stock, valued at $11,690,916.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Janus Henderson Group PLC lessened its stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 98.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,110 shares

Vanguard Group Inc. lifted its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 60.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,868,666 shares of the company's stoc

Price T Rowe Associates Inc. MD lifted its holdings in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 51.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,170,327 shares of the compan

ProShare Advisors LLC purchased a new stake in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 10,038 shares of the company's stock, valued at approximatel

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) has received a consensus recommendation of "Buy" from the eight analysts that are currently covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price objec

Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $45.93

Apogee Therapeutics (NASDAQ:APGE) Shares Up 4%

Apogee Therapeutics (NASDAQ:APGE) Sees Large Volume Increase

Jennison Associates LLC increased its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 192.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 302,892 shares of the company's stock after purchasing an additional 199,14

Capstone Investment Advisors LLC purchased a new stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 41,001 shares of the company's stock, valued at approxi

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 5,995 shares of the firm's stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total transaction of $225,412.00. Following the sale, the insider now directly owns 294,793 shares of the company's stock, valued at approximately $11,084,216.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Apogee Therapeutics (NASDAQ:APGE) Trading Down 2.7%

Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight brokerages that are covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 1-year t

Apogee Therapeutics (NASDAQ:APGE) Trading 5.3% Higher

Apogee Therapeutics (NASDAQ:APGE) Shares Down 3.6%

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) saw a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 6,500,000 shares, a growth of 36.0% from the May 15th total of 4,780,000 shares. Currently, 17.6% of the shares of the stock are short sold. Based on an average daily volume of 576,600 shares, the days-to-cover ratio is currently 11.3 days.

Blackstone Inc. raised its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 17.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 351,810 shares of the company's stock after buying an additional 52,688 shares duri

Apogee Therapeutics (NASDAQ:APGE) Shares Gap Up to $43.21

Braidwell LP grew its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 38.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 681,101 shares of the company's stock after buying an addition

TD Asset Management Inc grew its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 217.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 100,846 shares of the company's stock after purchasing an additional 69,052

Affinity Asset Advisors LLC decreased its position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 48.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 537,093 shares of the company's stock aft